Intensity Therapeutics Inc(INTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.83 | Insider Own | 3.92% | Shs Outstand | 3.3M | Perf Week | 4.62% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 35.16% | Insider Trans | - | Shs Float | 3.1M | Perf Month | 5.92% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.99 | Inst Own | 26.04% | Short Float | 2.8% | Perf Quarter | -20.19% |
| Income | -0.01B | P/S | - | EPS this Y | 59.46% | Inst Trans | 7.19% | Short Ratio | 3.44 | Perf Half Y | -34.49% |
| Sales | 0.00B | P/B | 1.09 | EPS next 5Y | 29.36% | ROA | -139.85% | Short Interest | 0.09M | Perf YTD | -66.85% |
| Book/sh | 3.13 | P/C | 1.16 | EPS past 3/5Y | 16.06% 5.76% | ROE | -195.88% | 52W High | -92.18% ($43.50) | Perf Year | -89.7% |
| Cash/sh | 2.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -120.34% | 52W Low | 13.33% ($3.00) | Perf 3Y | -95.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 76.63% | Gross Margin | - | Volatility(W/M) | 7.13% 9.24% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5 | EPS Q/Q | 66.95% | Profit Margin | - | RSI (14) | 47.36 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5 | Sales Q/Q | - | SMA20 | 0.34% ($3.39) | Beta | 3.08 | Target Price | $17.2 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/5 | SMA50 | -9.76% ($3.77) | Rel Volume | 0.63 | Prev Close | $3.34 |
| Employees | 16 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -27.22% - | SMA200 | -34.92% ($5.22) | Avg Volume(3M) | 0.03M | Price | $3.4 |
| IPO | 2023/6/30 | Option/Short | No/Yes | Trades | 109 | Volume | 16,120 | Change | 1.8% |
💉 This clinical-stage biotech develops INT230-6, a candidate cancer therapy based on a proprietary technology that is injected directly into solid tumors to kill cancer cells while also triggering an immune response. It is a U.S.-listed small-cap company currently running two trials simultaneously: the Phase 3 "INVINCIBLE-3" study in soft tissue sarcoma and the Phase 2 "INVINCIBLE-4" study in triple-negative breast cancer.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
Next earnings report: November 5
4 days to go.
INTS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.5% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -95.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 26.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #497 of 597 in the industry
Based on market cap of $11M.
INTS#497 Intensity Therapeutics Inc $11M PER - 
PASG#497 Passage Bio Inc $11M PER - 
LSTA#499 Lisata Therapeutics Inc $11M PER - 
GTBP#500 GT Biopharma Inc $11M PER - 
GDTC#501 CytoMed Therapeutics Ltd $11M PER - 
FAQ
What kind of company is INTS?
INTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INTS?
The market cap of INTS is approximately $11M, ranking 5,396 within its sector.
What is the 52-week high and low for INTS?
INTS has recorded a 52-week high of $43.50 and a low of $3.00.
